Answers are grounded in this paper and cite their sources.
Androgen receptor (AR) represents a pivotal molecular target in prostate cancer (PCa), rendering hormonal therapy a central role in clinical management. However, limited therapeutic efficacy is frequently observed due to AR overexpression, aberrant splicing, and metabolic reprogramming-mediated drug resistance. Herein, this study constructs MnS-GUL-CB839 (MGC) nanoplatform, which achieves efficient and targeted accumulation in PCa via active-targeting motif Glu-urea-Lys, potently downregulates the expression of AR and its splice variant AR-V7 , and reverses glutamine dependence. In acidic tumor microenvironment, MGC enables sustained release of manganese ions (Mn 2+ ), hydrogen sulfide (H 2 S) and the glutamine metabolism inhibitor CB839. Specifically, Mn 2+ represses transcription of AR and AR-V7 for AR signaling suppression. In parallel, H 2 S elevates intracellular hydrogen peroxide levels via inhibiting the catalytic activity of catalase, CB839 reverses glutamine addiction and diminishes glutathione production through inhibition of the rate-limiting enzyme in glutamine metabolism termed glutaminase 1. H 2 S and CB839 synergistically amplify Mn 2+ -catalyzed Fenton-like reactions, generating abundant hydroxyl radicals. Ultimately, this cascade realizes enhanced chemodynamic therapy (CDT) for ferroptosis and apoptosis induction. In summary, our findings underscore MGC as a promising nanoplatform to integrate AR signaling suppression, metabolic reprogramming and self-enhanced CDT, which establishes a unified therapeutic paradigm for PCa.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: